NASDAQ:AGMB AgomAb Therapeutics Q2 2026 Earnings Results & Report $8.72 -0.09 (-1.02%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more. AgomAb Therapeutics reported Q2 2026 earnings on August 6, 2026. The company reported EPS of -$0.4550. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeAfter Market ClosesConference Call4:00 PM ET AgomAb Therapeutics EPS ResultsActual EPS-$0.4550Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAgomAb Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) AgomAb Therapeutics Q2 2026 Earnings FAQ Did AgomAb Therapeutics beat earnings estimates for Q2 2026? AgomAb Therapeutics (NASDAQ:AGMB) reported earnings of -$0.4550 per share for Q2 2026. The report was announced on Thursday, August 6, 2026. AgomAb Therapeutics Earnings HeadlinesAgomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's DiseaseOctober 13 at 4:05 PM | globenewswire.comAgomAb Therapeutics (NASDAQ:AGMB) Director Acquires $44,500.00 in StockOctober 12 at 4:22 AM | americanbankingnews.comElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.October 14 at 1:00 AM | Behind the Markets (Ad)Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB) and Jade Biosciences (JBIO)October 12 at 3:05 AM | theglobeandmail.comInsider Move: AgomAb Therapeutics Director Makes a Bold New BetOctober 9, 2026 | tipranks.comAgomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-InflammationOctober 8, 2026 | marketscreener.comMSee More AgomAb Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AgomAb Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AgomAb Therapeutics and other key companies, straight to your email. Email Address About AgomAb TherapeuticsAgomAb Therapeutics (NASDAQ:AGMB) N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit. Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease. The company’s approach is intended to stimulate intestinal mucosal healing while limiting unwanted effects outside the gastrointestinal tract. In addition to AGMB-129, Agomab is advancing a broader pipeline of regenerative medicine programs addressing fibrosis, oncology and other conditions associated with tissue damage or impaired repair. The company was founded in 2017 and operates as a biotechnology company with activities in Europe and the United States.View AgomAb Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
